Bulletin
Investor Alert

Seattle Genetics Inc.

NAS: SGEN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 4, 2020, 7:30 p.m.

/zigman2/quotes/203326163/composite

$

165.99

Change

+0.92 +0.56%

Volume

Volume 23,910

Quotes are delayed by 20 min

/zigman2/quotes/203326163/composite

Today's close

$ 169.04

$ 165.07

Change

-3.97 -2.35%

Day low

Day high

$162.84

$168.73

Open

52 week low

52 week high

$65.44

$187.99

Open

Company Description

Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related can...

Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Valuation

Price to Sales Ratio

20.63

Price to Book Ratio

10.47

Enterprise Value to Sales

19.83

Total Debt to Enterprise Value

0.00

Efficiency

Revenue/Employee

571,161.00

Income Per Employee

-98,847.00

Receivables Turnover

4.80

Total Asset Turnover

0.49

Liquidity

Current Ratio

4.54

Quick Ratio

4.21

Cash Ratio

3.13

Profitability

Gross Margin

95.21

Operating Margin

-24.06

Pretax Margin

-17.31

Net Margin

-17.31

Return on Assets

-8.55

Return on Equity

-10.07

Return on Total Capital

-13.67

Return on Invested Capital

-9.86

Capital Structure

Total Debt to Total Equity

4.11

Total Debt to Total Capital

3.94

Total Debt to Total Assets

3.49

Long-Term Debt to Equity

3.60

Long-Term Debt to Total Capital

3.46

Officers and Executives

Name Age Officer Since Title
Dr. Clay B. Siegall 58 1997 Chairman, President & Chief Executive Officer
Mr. Todd E. Simpson 58 2005 Chief Financial Officer
Dr. Vaughn B. Himes 58 2009 Executive Vice President-Operations
Dr. Robert J. Lechleider - 2016 Senior Vice President-Clinical Development
Dr. Roger D. Dansey 62 2018 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
07/17/2020 Vaughn B. Himes
Chief Technical Officer
1,965   Disposition at $180.18 per share. 354,053
07/17/2020 Vaughn B. Himes
Chief Technical Officer
4,835   Disposition at $179.35 per share. 867,157
07/17/2020 Vaughn B. Himes
Chief Technical Officer
1,200   Disposition at $178.46 per share. 214,152
07/17/2020 Vaughn B. Himes
Chief Technical Officer
8,000   Derivative/Non-derivative trans. at $15.46 per share. 123,680
07/08/2020 Clay B. Siegall
President and CEO; Director
400   Disposition at $172.55 per share. 69,020
07/08/2020 Clay B. Siegall
President and CEO; Director
4,277   Disposition at $174.07 per share. 744,497
07/08/2020 Clay B. Siegall
President and CEO; Director
16,321   Disposition at $174.99 per share. 2,856,011
07/08/2020 Clay B. Siegall
President and CEO; Director
6,274   Disposition at $175.69 per share. 1,102,279
07/08/2020 Clay B. Siegall
President and CEO; Director
400   Disposition at $176.94 per share. 70,776
07/08/2020 Clay B. Siegall
President and CEO; Director
800   Disposition at $177.78 per share. 142,224
07/08/2020 Clay B. Siegall
President and CEO; Director
400   Derivative/Non-derivative trans. at $12 per share. 4,800
07/08/2020 Clay B. Siegall
President and CEO; Director
4,277   Derivative/Non-derivative trans. at $12 per share. 51,324
07/08/2020 Clay B. Siegall
President and CEO; Director
16,321   Derivative/Non-derivative trans. at $12 per share. 195,852
07/08/2020 Clay B. Siegall
President and CEO; Director
6,274   Derivative/Non-derivative trans. at $12 per share. 75,288
07/08/2020 Clay B. Siegall
President and CEO; Director
400   Derivative/Non-derivative trans. at $12 per share. 4,800
07/08/2020 Clay B. Siegall
President and CEO; Director
800   Derivative/Non-derivative trans. at $12 per share. 9,600
07/02/2020 Charles R. Romp
EVP, Commercial
712   Disposition at $167.49 per share. 119,252
07/01/2020 Todd E. Simpson
Chief Financial Officer
1,010   Disposition at $171.39 per share. 173,103
07/01/2020 Todd E. Simpson
Chief Financial Officer
139   Disposition at $170.18 per share. 23,655
07/01/2020 Todd E. Simpson
Chief Financial Officer
5,012   Disposition at $167.66 per share. 840,311
07/01/2020 Todd E. Simpson
Chief Financial Officer
4,112   Disposition at $166.99 per share. 686,662
07/01/2020 Todd E. Simpson
Chief Financial Officer
1,300   Disposition at $165.86 per share. 215,618
06/19/2020 Jean I. Liu
GC/EVP, Leg Affairs
9,877   Disposition at $165 per share. 1,629,705
06/17/2020 Roger D. Dansey
Chief Medical Officer
962   Disposition at $160.1 per share. 154,016
06/17/2020 Roger D. Dansey
Chief Medical Officer
300   Disposition at $158.47 per share. 47,541
06/17/2020 Roger D. Dansey
Chief Medical Officer
900   Disposition at $157.74 per share. 141,966
06/16/2020 Roger D. Dansey
Chief Medical Officer
838   Disposition at $157.15 per share. 131,691
06/15/2020 Roger D. Dansey
Chief Medical Officer
4,984   Disposition at $157.15 per share. 783,235
06/08/2020 Clay B. Siegall
President and CEO; Director
2,700   Disposition at $145.03 per share. 391,581
06/08/2020 Clay B. Siegall
President and CEO; Director
2,300   Disposition at $146.07 per share. 335,961
06/08/2020 Clay B. Siegall
President and CEO; Director
3,500   Disposition at $147 per share. 514,500
06/08/2020 Clay B. Siegall
President and CEO; Director
2,800   Disposition at $148.12 per share. 414,736
06/08/2020 Clay B. Siegall
President and CEO; Director
4,635   Disposition at $148.85 per share. 689,919
06/08/2020 Clay B. Siegall
President and CEO; Director
5,937   Disposition at $150.23 per share. 891,915
06/08/2020 Clay B. Siegall
President and CEO; Director
6,600   Disposition at $151.09 per share. 997,194
06/08/2020 Clay B. Siegall
President and CEO; Director
2,700   Derivative/Non-derivative trans. at $12 per share. 32,400
06/08/2020 Clay B. Siegall
President and CEO; Director
2,300   Derivative/Non-derivative trans. at $12 per share. 27,600
06/08/2020 Clay B. Siegall
President and CEO; Director
3,500   Derivative/Non-derivative trans. at $12 per share. 42,000
06/08/2020 Clay B. Siegall
President and CEO; Director
2,800   Derivative/Non-derivative trans. at $12 per share. 33,600
06/08/2020 Clay B. Siegall
President and CEO; Director
4,635   Derivative/Non-derivative trans. at $12 per share. 55,620
06/08/2020 Clay B. Siegall
President and CEO; Director
5,937   Derivative/Non-derivative trans. at $12 per share. 71,244
06/08/2020 Clay B. Siegall
President and CEO; Director
6,600   Derivative/Non-derivative trans. at $12 per share. 79,200
05/15/2020 Baker Bros. Advisors LP
Director
1,335   Award at $0 per share. 0
05/15/2020 Baker Bros. Advisors LP
Director
1,335   Award at $0 per share. 0
05/15/2020 Marc E. Lippman
Director
1,335   Award at $0 per share. 0
05/15/2020 Daniel G. Welch
Director
1,335   Award at $0 per share. 0
05/15/2020 Charles R. Romp
EVP, Commercial
3,444   Award at $0 per share. 0
05/15/2020 David W. Gryska
Director
1,335   Award at $0 per share. 0
05/15/2020 Srinivas Akkaraju
Director
1,335   Award at $0 per share. 0
05/15/2020 Nancy A. Simonian
Director
1,335   Award at $0 per share. 0
05/15/2020 John A. Orwin
Director
1,335   Award at $0 per share. 0
05/15/2020 Alpna H. Seth
Director
1,335   Award at $0 per share. 0
05/15/2020 Baker Bros. Advisors LP
Director
1,602,312   Disposition at $160 per share. 256,369,920
05/15/2020 Baker Bros. Advisors LP
Director
147,688   Disposition at $160 per share. 23,630,080
/news/latest/company/us/sgen

MarketWatch News on SGEN

  1. Seattle Genetics stock price target raised to $179 from $150 at J.P. Morgan

    7:45 a.m. July 21, 2020

    - Tomi Kilgore

  2. Charting a bull flag, S&P 500 holds the range top

    11:40 a.m. July 20, 2020

    - Michael Ashbaugh

  3. Anterix and Bausch Holding See Activist Action

    9:30 p.m. May 22, 2020

    - Barron's Online

  4. Macy’s and Portola See Investor Activists Buy Up Stakes

    6:41 p.m. May 15, 2020

    - Barron's Online

  5. Seattle Genetics started at outperform with $139 stock price target at BMO Capital

    10:17 a.m. Jan. 28, 2020

    - Tomi Kilgore

  6. Loading more headlines...
/news/nonmarketwatch/company/us/sgen

Other News on SGEN

  1. 10-Q: SEATTLE GENETICS INC /WA

    10:17 a.m. July 31, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  2. Wall Street Breakfast: Big Beats From Big Tech

    7:04 a.m. July 31, 2020

    - Seeking Alpha

  3. Seattle Genetics Q2 Earnings Preview

    5:35 p.m. July 29, 2020

    - Seeking Alpha

  4. Notable earnings after Thursday's close

    5:35 p.m. July 29, 2020

    - Seeking Alpha

  5. Seattle Genetics: Profitable Products, Exciting Pipeline

    12:32 p.m. July 29, 2020

    - Seeking Alpha

  6. Biotech Bonanza - Second Half Outlook

    8:24 a.m. July 28, 2020

    - Seeking Alpha

  7. 5 Goldman Sachs Conviction Buy Stocks With the Most Upside

    6:51 a.m. July 27, 2020

    - 247WallSt.com

  8. Stocks To Watch: Bank Earnings And SPAC Deals Blaze In

    8:25 a.m. July 11, 2020

    - Seeking Alpha

  9. Loading more headlines...

At a Glance

Seattle Genetics, Inc.

21823-30th Drive SE

Bothell, Washington 98021

Phone

1 4255274000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$916.71M

Net Income

$-158.65M

2019 Sales Growth

40.0%

Employees

1,605

/news/pressrelease/company/us/sgen

Press Releases on SGEN

  1. Seattle Genetics Reports Second Quarter 2020 Financial Results

    4:02 p.m. July 30, 2020

    - BusinessWire - BZX

  2. Nasdaq 100 Movers: SGEN, TCOM

    10:48 a.m. July 21, 2020

    - MarketNewsVideo.com

  3. IAU, FCTR: Big ETF Inflows

    10:47 a.m. July 14, 2020

    - MarketNewsVideo.com

  4. Loading more headlines...
Link to MarketWatch's Slice.